Table III. Summary of differentially excreted peptides from the discovery phase. p values were determined using the independent t-test and adjusted by Benjamini-Hochberg procedure (Q). Fold change represents the ratio of the mean log-transformed intensities of youths with type 1 diabetes (T1D) to healthy controls (HC). AHSG, alpha-2-HS-glycoprotein; ALB, albumin; APOA1, apolipoprotein A1; CLU, clusterin; LTBP4, latent transforming growth factor beta binding protein 4; FXYD2, Na+/K+-transporting ATPase subunit gamma; UMOD, uromodulin.
| Peptide | Name | Mass (Da) | Charge | Fold change (T1D–HC) | P | Q |
|---|---|---|---|---|---|---|
| SGSVIDQSRVLNLGPI | UMOD-1 | 1653.9050 | 2,3 | 2.11 | 0.0283 | 0.3298 |
| SGSVIDQSRVLNLGPITR | UMOD-2 | 1911.0538 | 2,3,4 | 0.68 | 0.0170 | 0.2768 |
| SVIDQSRVLNLGPI | UMOD-3 | 1509.8515 | 1,2 | 6.72 | 0.0001 | 0.0070 |
| SVIDQSRVLNLGPIT | UMOD-4 | 1610.8992 | 1,2,3 | 3.95 | 0.0003 | 0.0127 |
| SVIDQSRVLNLGPITR | UMOD-5 | 1767.0003 | 2,3,4 | 3.84 | <0.0001 | 0.0003 |
| SVIDQSRVLNLGPITRK | UMOD-6 | 1895.0952 | 2,3,4 | 3.75 | 0.0035 | 0.0820 |
| VIDQSRVLNLGPI | UMOD-7 | 1422.8195 | 1,2 | 5.48 | 0.0005 | 0.0159 |
| DDGGPYGESEAPAPPGPGTRWP | LTBP4 | 2208.9712 | 2,3 | 0.65 | 0.0450 | 0.4894 |
| TGLSMDGGGSPKGDVDPF | FXYD2 | 1735.7723 | 2 | 0.38 | 0.0093 | 0.1901 |
| SHTSDSDVPSGVTEVVVKL | CLU-1 | 1954.9848 | 2,3 | 2.55 | 0.0195 | 0.2891 |
| HTSDSDVPSGVTEVVVKL | CLU-2 | 1867.9527 | 2,3 | 5.87 | 0.0001 | 0.0096 |
| LSALEEYTKKLNTQ | APOA1 | 1636.8672 | 2,3 | 5.88 | 0.0217 | 0.2948 |
| YGEMADCCAKQEPERNECFLQ | ALB-1 | 2634.0607 | 2,3 | 2.12 | 0.0138 | 0.2503 |
| VRYTKKVPQVSTPTL | ALB-2 | 1715.9934 | 2,3,4 | 4.64 | 0.0245 | 0.3067 |
| TVVQPSVGAAAGPVVPPCPGRIRH | AHSG | 2421.3063 | 3,4 | 1.92 | 0.0019 | 0.0529 |